Found 25 results
Filters: First Letter Of Last Name is C  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas., Culjkovic-Kraljacic, Biljana, Fernando Tharu M., Marullo Rossella, Calvo-Vidal Nieves, Verma Akanksha, Yang ShaoNing, Tabbò Fabrizio, Gaudiano Marcello, Zahreddine Hiba, Goldstein Rebecca L., et al. , Blood, 2016 Feb 18, Volume 127, Issue 7, p.858-68, (2016)
Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma., Cubedo, Elena, Gentles Andrew J., Huang ChuanXin, Natkunam Yasodha, Bhatt Shruti, Lu Xiaoqing, Jiang Xiaoyu, Romero-Camarero Isabel, Freud Aharon, Zhao Shuchun, et al. , Blood, 2012 Jun 07, Volume 119, Issue 23, p.5478-91, (2012)
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma., Clozel, Thomas, Yang ShaoNing, Elstrom Rebecca L., Tam Wayne, Martin Peter, Kormaksson Matthias, Banerjee Samprit, Vasanthakumar Aparna, Culjkovic Biljana, Scott David W., et al. , Cancer Discov, 2013 Sep, Volume 3, Issue 9, p.1002-19, (2013)
The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL., Ci, Weimin, Polo Jose M., Cerchietti Leandro, Shaknovich Rita, Wang Ling, Yang Shao Ning, Ye Kenny, Farinha Pedro, Horsman Douglas E., Gascoyne Randy D., et al. , Blood, 2009 May 28, Volume 113, Issue 22, p.5536-48, (2009)
B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma., Ci, Weimin, Polo Jose M., and Melnick Ari , Curr Opin Hematol, 2008 Jul, Volume 15, Issue 4, p.381-90, (2008)
Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia., Chung, Stephen S., Kim Eunhee, Park Jae H., Chung Young Rock, Lito Piro, Teruya-Feldstein Julie, Hu Wenhuo, Béguelin Wendy, Monette Sebastien, Duy Cihangir, et al. , Sci Transl Med, 2014 May 28, Volume 6, Issue 238, p.238ra71, (2014)
CD99 is a therapeutic target on disease stem cells in myeloid malignancies., Chung, Stephen S., Eng William S., Hu Wenhuo, Khalaj Mona, Garrett-Bakelman Francine E., Tavakkoli Montreh, Levine Ross L., Carroll Martin, Klimek Virginia M., Melnick Ari M., et al. , Sci Transl Med, 2017 01 25, Volume 9, Issue 374, (2017)
Unique Immune Cell Coactivators Specify Locus Control Region Function and Cell Stage., Chu, Chi-Shuen, Hellmuth Johannes C., Singh Rajat, Ying Hsia-Yuan, Skrabanek Lucy, Teater Matthew R., Doane Ashley S., Elemento Olivier, Melnick Ari M., and Roeder Robert G. , Mol Cell, 2020 Dec 03, Volume 80, Issue 5, p.845-861.e10, (2020)
ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein., Chevallier, Nathalie, Corcoran Connie M., Lennon Christine, Hyjek Elizabeth, Chadburn Amy, Bardwell Vivian J., Licht Jonathan D., and Melnick Ari , Blood, 2004 Feb 15, Volume 103, Issue 4, p.1454-63, (2004)
Identification of Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design., Cheng, Huimin, Linhares Brian M., Yu Wenbo, Cardenas Mariano G., Ai Yong, Jiang Wenjuan, Winkler Alyssa, Cohen Sandra, Melnick Ari, MacKerell Alexander, et al. , J Med Chem, 2018 Sep 13, Volume 61, Issue 17, p.7573-7588, (2018)
SYK inhibition and response prediction in diffuse large B-cell lymphoma., Cheng, Shuhua, Coffey Greg, X Zhang Hannah, Shaknovich Rita, Song Zibo, Lu Pin, Pandey Anjali, Melnick Ari M., Sinha Uma, and Y Wang Lynn , Blood, 2011 Dec 08, Volume 118, Issue 24, p.6342-52, (2011)
Corrigendum: Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia., Chen, Zhengshan, Shojaee Seyedmehdi, Buchner Maike, Geng Huimin, Lee Jae Woong, Klemm Lars, Titz Björn, Graeber Thomas G., Park Eugene, Tan Ying Xim, et al. , Nature, 2016 06 02, Volume 534, Issue 7605, p.138, (2016)
Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes., Chambwe, Nyasha, Kormaksson Matthias, Geng Huimin, De Subhajyoti, Michor Franziska, Johnson Nathalie A., Morin Ryan D., Scott David W., Godley Lucy A., Gascoyne Randy D., et al. , Blood, 2014 Mar 13, Volume 123, Issue 11, p.1699-708, (2014)
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo., Cerchietti, Leandro C., Yang Shao Ning, Shaknovich Rita, Hatzi Katerina, Polo Jose M., Chadburn Amy, Dowdy Steven F., and Melnick Ari , Blood, 2009 Apr 09, Volume 113, Issue 15, p.3397-405, (2009)
A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo., Cerchietti, Leandro C., Ghetu Alexandru F., Zhu Xiao, Da Silva Gustavo F., Zhong Shijun, Matthews Marilyn, Bunting Karen L., Polo Jose M., Farès Christophe, Arrowsmith Cheryl H., et al. , Cancer Cell, 2010 Apr 13, Volume 17, Issue 4, p.400-11, (2010)
BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy., Cerchietti, Leandro C., Hatzi Katerina, Caldas-Lopes Eloisi, Yang Shao Ning, Figueroa Maria E., Morin Ryan D., Hirst Martin, Mendez Lourdes, Shaknovich Rita, Cole Philip A., et al. , J Clin Invest, 2010 Dec 01, Volume 120, Issue 12, p.4569-82, (2010)
Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment?, Cerchietti, Leandro, and Melnick Ari , Expert Rev Hematol, 2013 Aug, Volume 6, Issue 4, p.343-5, (2013)
DNA Methylation-Based Biomarkers., Cerchietti, Leandro, and Melnick Ari , J Clin Oncol, 2017 03, Volume 35, Issue 7, p.793-795, (2017)
Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas., Cerchietti, Leandro, Damm-Welk Christine, Vater Inga, Klapper Wolfram, Harder Lana, Pott Christiane, Yang Shao Ning, Reiter Alfred, Siebert Reiner, Melnick Ari, et al. , PLoS One, 2011 Apr 08, Volume 6, Issue 4, p.e18436, (2011)
Sequential transcription factor targeting for diffuse large B-cell lymphomas., Cerchietti, Leandro C., Polo Jose M., Da Silva Gustavo F., Farinha Pedro, Shaknovich Rita, Gascoyne Randy D., Dowdy Steven F., and Melnick Ari , Cancer Res, 2008 May 01, Volume 68, Issue 9, p.3361-9, (2008)
A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas., Cerchietti, Leandro C., Lopes Eloisi C., Yang Shao Ning, Hatzi Katerina, Bunting Karen L., Tsikitas Lucas A., Mallik Alka, Robles Ana I., Walling Jennifer, Varticovski Lyuba, et al. , Nat Med, 2009 Dec, Volume 15, Issue 12, p.1369-76, (2009)
The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target., Cardenas, Mariano G., Oswald Erin, Yu Wenbo, Xue Fengtian, MacKerell Alexander D., and Melnick Ari M. , Clin Cancer Res, 2017 Feb 15, Volume 23, Issue 4, p.885-893, (2017)
Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma., Cardenas, Mariano G., Yu Wenbo, Béguelin Wendy, Teater Matthew R., Geng Huimin, Goldstein Rebecca L., Oswald Erin, Hatzi Katerina, Yang Shao-Ning, Cohen Joanna, et al. , J Clin Invest, 2016 09 01, Volume 126, Issue 9, p.3351-62, (2016)
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models., Caldas-Lopes, Eloisi, Cerchietti Leandro, Ahn James H., Clement Cristina C., Robles Ana I., Rodina Anna, Moulick Kamalika, Taldone Tony, Gozman Alexander, Guo Yunke, et al. , Proc Natl Acad Sci U S A, 2009 May 19, Volume 106, Issue 20, p.8368-73, (2009)
NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem c, Cairo, Mitchell S., Jordan Craig T., Maley Carlo C., Chao Clifford, Melnick Ari, Armstrong Scott A., Shlomchik Warren, Molldrem Jeff, Ferrone Soldano, Mackall Crystal, et al. , Biol Blood Marrow Transplant, 2010 Jun, Volume 16, Issue 6, p.709-28, (2010)